Mechanisms of Disease: survival benefit of temsirolimus validates a role for mTOR in the management of advanced RCC
- 8 July 2008
- journal article
- review article
- Published by Springer Nature in Nature Clinical Practice Oncology
- Vol. 5 (10) , 601-609
Abstract
Mammalian target of rapamycin (mTOR) is an important and clinically relevant therapeutic target. Temsirolimus has significantly improved overall survival rates in patients with advanced renal cell carcinoma, thereby validating the importance of mTOR in the natural history of this disease. This Review discusses the clinical development of temsirolimus, its novel mechanism of action, and the investigational strategies for targeting mTOR in other tumor types. Temsirolimus is a specific inhibitor of mammalian target of rapamycin (mTOR) that is approved for the treatment of advanced renal cell carcinoma. mTOR is unique among antitumor drug targets because it is a convergence point for many signaling pathways. Activation of mTOR by various growth signals increases the synthesis of proteins needed for cell-cycle progression and tumor growth. Temsirolimus demonstrates a significant improvement in overall survival in patients with advanced renal cell carcinoma and poor-prognostic features, thereby validating the importance of mTOR in the natural history of this disease. mTOR might also be an important target in other tumor types, and more than 100 ongoing clinical trials are designed to identify additional malignancies that respond to temsirolimus and other mTOR inhibitors, either alone or in combination with other targeted agents or chemotherapy.Keywords
This publication has 56 references indexed in Scilit:
- The Role of Mammalian Target of Rapamycin Inhibitors in the Treatment of Advanced Renal CancerClinical Cancer Research, 2007
- Sorafenib in Advanced Clear-Cell Renal-Cell CarcinomaNew England Journal of Medicine, 2007
- Predicted mechanisms of resistance to mTOR inhibitorsBritish Journal of Cancer, 2006
- Antiangiogenic Potential of the Mammalian Target of Rapamycin Inhibitor TemsirolimusCancer Research, 2006
- Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancerNature Medicine, 2005
- Phase II Trial of Single-Agent Temsirolimus (CCI-779) for Relapsed Mantle Cell LymphomaJournal of Clinical Oncology, 2005
- Phase II study of CCI-779 in patients with recurrent glioblastoma multiformeInvestigational New Drugs, 2005
- O-158 A randomized phase II ECOG trial of two dose levels of temsirolimus (CCI-779) in patients with extensive stage small cell lung cancer in remission after induction therapyLung Cancer, 2005
- mTOR Interacts with Raptor to Form a Nutrient-Sensitive Complex that Signals to the Cell Growth MachineryCell, 2002
- A mammalian protein targeted by G1-arresting rapamycin–receptor complexNature, 1994